Skip to main content
Weifeng Lao on Muck Rack

Weifeng Lao

As seen in: Nature, BMC Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Weifeng

Contact Weifeng, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The landscape of tissue-resident microbiota across normal, polyp, and colorectal cancer tissues - Nature Communications

|
By Haoyi Xiang, Baining Shen, Weifeng Lao, Bingjun Bai, Min Chen, Leqi Zhou, Guanyu Yu, Wei Zhang, Huan Chen, Yuhao Wang, Hangjin Jiang, Zhangfa Song
| Nature Verified
Abstract Emerging evidence suggests that tissue-resident microbiota (TRM) is associated with tumor biology; however, their distribution and compositional characteristics across different colorectal tissue types remain incompletely defined. Here, we conducted a comprehensive cross-sectional analysis of TRM distribution and abundance across 1134 clinical specimens, including normal mucosa, precancerous polyps, and colorectal cancer (CRC) tissues.
Open in Who Shared Issue with article?

Node-sparing modified short-course Radiotherapy Combined with CAPOX and Tislelizumab for locally Advanced MSS of Middle and low rectal Cancer (mRCAT): an open-label, single-arm, prospective, multicentre clinical trial | BMC Cancer | Full Text

|
By Cheng Cai, Xia Zhang, Xiaonan Sun, Li Chen, Jianping Wang, Xuefeng Huang, Weifeng Lao, Xiaowei Wang, Min Chen, Jinlin Du, Zhangfa Song, Huogang Wang, Engeng Chen, Benxing Gu, Shubo Ding
| BMC Cancer Verified
The study is an open-label, single-arm, multicentre, prospective phase II trial. MSS/pMMR LARC Patients will receive node-sparing modified short-course radiotherapy (25 Gy/5f). The irradiated planned target volume will only include the primary tumour bed but not the tumour-draining lymph nodes, followed by 3 cycles of capecitabine plus oxaliplatin (CAPOX) chemotherapy and tislelizumab. Then, patients will undergo TME. The pCR rate, adverse effects, and long-term prognosis will be analysed.
Open in Who Shared Issue with article?
See all 2 articles